Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REGN
DateTimeSourceHeadlineSymbolCompany
10/02/202216:59PR Newswire (US)FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic DermatitisNASDAQ:REGNRegeneron Pharmaceuticals Inc
10/02/202202:27Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:REGNRegeneron Pharmaceuticals Inc
08/02/202201:27Edgar (US Regulatory)Annual Report (10-k)NASDAQ:REGNRegeneron Pharmaceuticals Inc
04/02/202223:30Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:REGNRegeneron Pharmaceuticals Inc
04/02/202222:30PR Newswire (US)Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating ResultsNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/02/202209:13Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:REGNRegeneron Pharmaceuticals Inc
02/02/202208:29PR Newswire (US)Positive Dupixent® (dupilumab) Data Across Five Diseases with Underlying Type 2 Inflammation to be Presented at 2022 AAAAI Annual MeetingNASDAQ:REGNRegeneron Pharmaceuticals Inc
31/01/202216:59PR Newswire (US)CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 InflammationNASDAQ:REGNRegeneron Pharmaceuticals Inc
29/01/202204:45TipRanksH.C. Wainwright Sticks to Their Buy Rating for Regeneron (REGN)NASDAQ:REGNRegeneron Pharmaceuticals Inc
28/01/202223:54Dow Jones NewsRegeneron, Sanofi Pull FDA Application for Libtayo in Advanced Cervical CancerNASDAQ:REGNRegeneron Pharmaceuticals Inc
28/01/202223:00PR Newswire (US)Regeneron and Sanofi Provide Regulatory Update on Libtayo® (cemiplimab-rwlc) in Advanced Cervical CancerNASDAQ:REGNRegeneron Pharmaceuticals Inc
21/01/202204:00PR Newswire (US)Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent SearchNASDAQ:REGNRegeneron Pharmaceuticals Inc
21/01/202204:00PR Newswire (US)Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent SearchNASDAQ:REGNRegeneron Pharmaceuticals Inc
20/01/202204:25TipRanksRegeneron (REGN) Received its Third Buy in a RowNASDAQ:REGNRegeneron Pharmaceuticals Inc
19/01/202223:52Dow Jones NewsRegeneron Says FDA to Review Libtayo/Chemotherapy Combo in First-Line NSCLC TreatmentNASDAQ:REGNRegeneron Pharmaceuticals Inc
19/01/202223:00PR Newswire (US)FDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLCNASDAQ:REGNRegeneron Pharmaceuticals Inc
19/01/202216:59PR Newswire (US)Second Positive Phase 3 Dupixent® (dupilumab) Trial Confirms Significant Improvements for Patients with Prurigo NodularisNASDAQ:REGNRegeneron Pharmaceuticals Inc
14/01/202208:05PR Newswire (US)Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast onNASDAQ:REGNRegeneron Pharmaceuticals Inc
12/01/202204:07TipRanksRegeneron Pharmaceuticals: Starting 2022 with Great ExpectationsNASDAQ:REGNRegeneron Pharmaceuticals Inc
11/01/202204:45TipRanksRegeneron (REGN) Receives a Buy from H.C. WainwrightNASDAQ:REGNRegeneron Pharmaceuticals Inc
10/01/202222:54Dow Jones NewsRegeneron's Covid-19 Antibody Cocktail Had 2021 U.S. Sales Near $6 BillionNASDAQ:REGNRegeneron Pharmaceuticals Inc
10/01/202222:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:REGNRegeneron Pharmaceuticals Inc
08/01/202200:06TipRanksRegeneron Collaborates with Ultragenyx to Commercialize Evkeeza Outside U.S.NASDAQ:REGNRegeneron Pharmaceuticals Inc
07/01/202223:49Dow Jones NewsRegeneron, Ultragenyx Ink International Deal on Cholesterol Drug EvkeezaNASDAQ:REGNRegeneron Pharmaceuticals Inc
07/01/202223:00PR Newswire (US)Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United StatesNASDAQ:REGNRegeneron Pharmaceuticals Inc
06/01/202208:26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
06/01/202208:24Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
06/01/202208:24Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
06/01/202208:23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
06/01/202208:23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:REGN